Controlled Crystallization During Freeze-Drying - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Controlled Crystallization During Freeze-Drying
The authors discuss the preparation of lipophilic drug nanocrystals by controlled crystallization during freeze-drying.

Pharmaceutical Technology
Volume 35, Issue 8, pp. 58-62

Figure 3: Dissolution profiles of fenofibrate from tablets composed of physical mixtures (open symbols), dispersions prepared by the batch process (black symbols), and dispersions prepared by the semicontinuous process (gray symbols). The tablets contained 30% (circular symbols) and 40% (square symbols) w/w fenofibrate in mannitol. (n=3–6; mean). (FIGURE 3 IS COURTESY OF THE AUTHORS)
After 15 min on a precooled freeze-dryer shelf, only the TBA peak can be seen in the Raman spectrum (see Figure 2). This indicates that at this stage of the process, the solvents were still in the liquid state and that the solutes were still dissolved in these solvents. After 75 min, the intensity of the peak corresponding to ice increased, and the width of the TBA peak decreased. However, no significant change in the relative intensities of either fenofibrate or mannitol peaks could be seen, which shows that during the freezing step, the solvents crystallized and that, importantly, the solutes did not. During equilibration at –50 C the solutes still did not crystallize.

However, when the temperature was increased to –25 C and maintained for 500 min, mannitol and fenofibrate peaks increased. This increase in intensity finished well before the drying step was initiated, indicating that crystalline mannitol and crystalline fenofibrate were formed during the crystallization step and that this crystallization was finished before drying started. To initiate drying, the pressure was decreased at 2963 min. The intensity of the water peak decreased and the width of the TBA peak increased thus indicating that sublimation of the solvents had begun. In summary, upon freezing, only the solvents crystallized, while the solutes did not crystallize until the temperature in the freeze-dryer was increased. Crystallization of the solutes finished before drying started.

From freeze-drying to spray freeze-drying using a three-way nozzle. Because only small quantities can be prepared in vials in the initial experiment, this freeze-drying process is not suitable for large-scale production. Therefore, a three-way nozzle was tested to determine if it could convert the small-batch freeze-drying process into a semicontinuous spray freeze-drying process for scale-up.

Solid dispersions prepared by freeze-drying (freezing in liquid nitrogen) and spray freeze-drying were compared. The dissolution rate of fenofibrate from dispersions prepared by the semicontinuous spray freeze-drying process was faster, especially at a higher drug load, than that of dispersions prepared by the small-batch freeze-drying process (see Figure 3).

Figure 4: Scanning-electron microscopy pictures of controlled crystallized dispersions prepared by freeze-drying (top) and spray freeze-drying (bottom). (FIGURE 4 IS REPRINTED FROM H. DE WAARD ET AL.,EUR. JRNL. OF PHARM. SCI. 38, 224–229 (2009), WITH PERMISSION FROM ELSEVIER.)
Because dispersions obtained from the different processes were all fully crystalline, the differences in dissolution rate should be attributed to differences in drug crystal size. Indeed, the SEM pictures indicate that crystals obtained from the semicontinuous process were smaller than those obtained from the batch process (see Figure 4). However, in-line Raman spectroscopy measurements showed that the solutes did not crystallize upon freezing, but after the temperature of the freeze-dryer shelf was increased.

Therefore, the difference in drug crystal size can be explained by the difference in freezing rate (11). During the batch process, vials containing 2 mL solution were immersed in liquid nitrogen, whereas during the semi-continuous process very small droplets were sprayed into liquid nitrogen. Because the volumes of the individual droplets were smaller than the volume of liquid in the vial, rapid freezing rates could be achieved by spray-freezing into liquid nitrogen (12).

Figure 5: A diagram of the controlled crystallization process. The white areas represent the solvent crystals, the grey areas the freeze concentrated fraction, and the black squares the drug nanocrystals. (FIGURE 5 IS COURTESY OF THE AUTHORS)
A higher freezing rate leads to the formation of smaller solvent crystals, and therefore smaller interstitial spaces (containing the freeze-concentrated fraction) between the solvent crystals (13). Because the drug and matrix crystallize in the freeze-concentrated fraction, the size of the drug crystals is limited to the size of these interstitial spaces. Thus, when smaller interstitial spaces are formed, the final drug crystal size is smaller (see Figure 5).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here